CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014
Revenues:
License and milestone fees	$ 10,692	$ 41,417	$ 16,762	$ 47,651
Royalty revenue	195	4,625	195	8,791
Non-cash royalty revenue related to the sale of future royalties	6,291		11,975
Research and development support	848	832	1,620	1,608
Clinical materials revenue	3	1,426	2,328	3,453
Total revenues	18,029	48,300	32,880	61,503
Operating Expenses:
Research and development	38,199	27,647	73,331	55,665
General and administrative	8,054	6,872	16,383	13,967
Total operating expenses	46,253	34,519	89,714	69,632
(Loss) income from operations	(28,224)	13,781	(56,834)	(8,129)
Investment income, net	60	14	111	22
Non-cash interest expense on liability related to the sale of future royalties	(5,059)		(10,202)
Other expense, net	(4)	(160)	(42)	(540)
Net (loss) income	$ (33,227)	$ 13,635	$ (66,967)	$ (8,647)
Basic and diluted net (loss) income per common share (in dollars per share)	$ (0.38)	$ 0.16	$ (0.77)	$ (0.10)
Basic weighted average common shares outstanding (in shares)	86,970	85,935	86,904	85,904
Dilutive impact of potential common shares (in shares)		730
Diluted weighted average common shares outstanding (in shares)	86,970	86,665	86,904	85,904
Total comprehensive (loss) income	$ (33,227)	$ 13,635	$ (66,967)	$ (8,647)